Sangamo Therapeutics, Inc.
SGMO
$0.5863
$0.01312.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 565.52% | 239.92% | -67.20% | -74.04% | -94.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 565.52% | 239.92% | -67.20% | -74.04% | -94.38% |
| Cost of Revenue | -38.55% | -50.56% | -51.61% | -43.53% | -33.75% |
| Gross Profit | 86.14% | 80.11% | 0.93% | -95.13% | -341.76% |
| SG&A Expenses | -26.26% | -24.55% | -29.70% | -27.88% | -22.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.70% | -45.12% | -47.08% | -40.33% | -31.42% |
| Operating Income | 71.40% | 67.57% | 16.05% | -22.76% | -104.90% |
| Income Before Tax | 74.45% | 76.11% | 62.68% | 46.92% | -21.65% |
| Income Tax Expenses | -116.50% | 97.17% | 96.71% | 99.74% | 120.24% |
| Earnings from Continuing Operations | 74.64% | 75.78% | 62.01% | 45.96% | -25.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.64% | 75.78% | 62.01% | 45.96% | -25.78% |
| EBIT | 71.40% | 67.57% | 16.05% | -22.76% | -104.90% |
| EBITDA | 72.22% | 67.80% | 8.45% | -38.87% | -126.80% |
| EPS Basic | 79.44% | 79.41% | 64.66% | 48.16% | -16.34% |
| Normalized Basic EPS | 75.81% | 72.28% | 16.53% | -29.60% | -99.30% |
| EPS Diluted | 78.78% | 78.91% | 64.18% | 48.23% | -15.24% |
| Normalized Diluted EPS | 75.65% | 72.14% | 16.48% | -29.50% | -98.66% |
| Average Basic Shares Outstanding | 21.20% | 18.79% | 15.07% | 12.49% | 11.04% |
| Average Diluted Shares Outstanding | 22.01% | 19.63% | 15.82% | 13.25% | 10.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |